Hb cycling remains one of the most persistent challenges in anemia management, driven by variable ESA responsiveness and overly frequent dose modifications (Jörg et al., 2023; Collins et al., 2005; Thanakitcharu and Jirajan, 2016). The gene discussed is GSTM1; the disease is anemia.